Independent prognostic significance of day 21 cytogenetic findings in newly-diagnosed acute myeloid leukemia or refractory anemia with excess blasts

Haematologica

Volumn 88, Issue 7, 2003, Pages 733-736

  Konopleva, Marina ^a   Cheng, Su Chun ^b   Cortes, Jorge E ^c   Hayes, Kimberly J ^d   Pierce, Sherry A ^c   Andreeff, Michael ^a,c   Giles, Francis J ^c   O'Brien, Susan ^c   Kantarjian, Hagop M ^c   Estey, Elihu H ^c,d  

^a Section of Molecular Hematology and Therapy   (United States)

^b Biostatistics   (United States)

^c Departments of Leukemia   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

AML; Day 21 cytogenetics

Indexed keywords

CYCLOPHOSPHAMIDE; CYTARABINE; FLUDARABINE; IDARUBICIN; TOPOTECAN;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; BLAST CELL; CANCER SURVIVAL; CHROMOSOME 5; CYTOGENETICS; HUMAN; MAJOR CLINICAL STUDY; MEDICAL DECISION MAKING; METAPHASE; PROGNOSIS; REFRACTORY ANEMIA;

ACUTE DISEASE; ANEMIA, REFRACTORY; CYTOGENETIC ANALYSIS; DISEASE-FREE SURVIVAL; HUMANS; LEUKEMIA, MYELOID; METAPHASE; MIDDLE AGED; TIME FACTORS; TREATMENT OUTCOME;

EID: 0038038463     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (8)

1. Simon R. Importance of prognostic factors in cancer clinical trials. Cancer Treat Rep 1984;68:185-92.
2. Bloomfield CD, Lawrence D, Byrd JC, Carroll A, Pettenati MJ, Tantravahi R, et al. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res 1998;58:4173-9.
3. Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 1998;92:2322-33.
4. Slovak ML, Kopecky KJ, Cassileth PA, Harrington DH, Theil KS, Mohamed A, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest oncology group/Eastern cooperative oncology group study. Blood 2000;96:4075-83.
5. Estey EH, Thall PF, Cortes JE, Giles FJ, O'Brien S, Pierce SA, et al. Comparison of idarubicin + ara-C-, fludarabine + ara-C-, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts. Blood 2001;98:3575-83.
6. Cox DR. Regression models and life tables. J R Stat Soc B 1972;34:187.
7. Thall PF, Estey EH. Graphical methods for evaluating covariate effects in the Cox model. In: Crowley J, editor. Handbook of Statistics in Clinical Oncology. New York, Basel: Marcel Dekker, Inc.; 2001. p. 411-31.
8. Freireich EJ, Cork A, Stass SA, McCredie KB, Keating MJ, Estey EH, et al. Cytogenetics for detection of minimal residual disease in acute myeloblastic leukemia. Leukemia 1992;6:500-6.